ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio consisting of its four most advanced product candidates directed at large unmet medical needs and major commercial markets. ACADIA’s pipeline includes pimavanserin in Phase III for Parkinson’s disease psychosis, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and ACP-16 in IND-track development. All of the product candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s headquarters are located in San Diego, California, and it maintain research and development operations in both San Diego and Malmo, Sweden.